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Magnetic Resonance Imaging as a Predictor of Survival Free of
Life-Threatening Arrhythmias and Transplantation in Cardiac
Sarcoidosis
Kaj Ekstr€om, MD; Jukka Lehtonen, MD; Helena H€anninen, MD; Riina Kandolin, MD; Sari Kivist€o, MD; Markku Kupari, MD
Background-—Cardiac magnetic resonance imaging has a key role in today’s diagnosis of cardiac sarcoidosis. We set out to
investigate whether cardiac magnetic resonance imaging also helps predict outcome in cardiac sarcoidosis.
Methods and Results-—Our work involved 59 patients with cardiac sarcoidosis (38 female, mean age 4610 years) seen at our
hospital since February 2004 and followed up after contrast-enhanced cardiac magnetic resonance imaging. The extent of
myocardial late gadolinium enhancement (measured as percentage of left ventricular mass), the volumes and ejection fractions of
the left and right ventricles, and the thickness of the basal interventricular septum were determined and analyzed for prognostic
signiﬁcance. By April 2015, 23 patients had reached the study’s end point, consisting of a composite of cardiac death (n=3),
cardiac transplantation (n=1), and occurrence of life-threatening ventricular tachyarrhythmias (n=19; ventricular ﬁbrillation in 5 and
sustained ventricular tachycardia in 14 patients). In univariate analysis, myocardial extent of late gadolinium enhancement
predicted event-free survival, as did scar-like thinning (<4 mm) of the basal interventricular septum and the ejection fraction of the
right ventricle (P<0.05 for all). In multivariate Cox regression analysis, extent of late gadolinium enhancement was the only
independent predictor of outcome events on cardiac magnetic resonance imaging, with a hazard ratio of 2.22 per tertile (95% CI
1.07–4.59). An extent of late gadolinium enhancement >22% (third tertile) had positive and negative predictive values for serious
cardiac events of 75% and 76%, respectively.
Conclusions-—Findings on cardiac magnetic resonance imaging and the extent of myocardial late gadolinium enhancement in
particular help predict serious cardiac events in cardiac sarcoidosis. ( J Am Heart Assoc. 2016;5:e003040 doi: 10.1161/
JAHA.115.003040)
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C ardiac sarcoidosis (CS) presents clinically either as onecomponent of a manifest multiorgan disease or, increas-
ingly, as an isolated heart condition.1 Although its prognosis
appears improved,1 CS still poses a threat to both quality and
duration of life. In the current therapeutic era, including active
cardiac transplant surgery, death from terminal heart failure is
rarely seen in CS. Fatal arrhythmias, instead, explain 90% of
cardiac mortality, and aborted arrhythmic deaths are as
common as all cardiac fatalities together.1 Implantable
cardioverter-deﬁbrillator (ICD) therapy is able to prevent
sudden death in CS,2 but its complications cannot be ignored,
and today’s experts advocate implantations only in patients at
high risk of fatal arrhythmias.3 Individual risk assessment is
problematic, however, because there are no large outcome
studies in CS. The general signs of poor cardiac prognosis,
such as spontaneous ventricular tachyarrhythmias and
impaired left ventricular (LV) function, are also applicable to
CS,3 but additional risk markers more speciﬁc to CS are
clearly needed. Myocardial late gadolinium enhancement
(LGE) on cardiac magnetic resonance imaging (CMRI) has been
reported to predict serious cardiac events in patients with
extracardiac sarcoidosis,4–7 although not consistently.8–10
Whether CMRI has prognostic value in established CS is
much less studied.11,12 LGE can expose areas of myocardial
injury and ﬁbrotic scarring that may serve as substrate to
ventricular tachyarrhythmias in CS.13 We analyzed a 10-year
series of consecutive CS patients to assess whether and how
CMRI is predictive of cardiac events including life-threatening
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arrhythmias. Our data support extent of myocardial LGE as a
strong risk marker in CS and suggest that impaired right
ventricular (RV) function and scar-like thinning of the basal
interventricular septum also are predictive of cardiac events.
Methods
Study Population and Data Collection
From February 2004 through July 2014, a total of 119
patients with CS were seen at Helsinki University Central
Hospital. Our institution directly serves a population of
1.9 million in the diagnosis and treatment of severe myocar-
dial diseases but also receives referrals from other university
hospitals because ours is the only transplant center in Finland.
Our strategy and practice of diagnostic procedures for
suspected CS have been described in detail previously.14–16
The diagnosis of CS requires documentation of sarcoidosis
histology in a biopsy sample of myocardium or, if that is
missing, extracardiac histology of sarcoidosis combined with
clinical manifestations and abnormalities in either CMRI or
18F-ﬂuorodeoxyglucose positron emission tomography or
echocardiography indicative of myocardial involvement. These
criteria are in conformity with the criteria advocated recently
in an expert consensus report.3 Of the 119 patients, 60 had
undergone gadolinium-enhanced CMRI and were eligible for
the present investigation. One-third of those patients were
referred from the other university hospitals, and the rest were
from our own catchment area. One patient was found to have
extensive coronary artery disease and was excluded from the
analyses. The hospital charts for the remaining 59 patients
(Figure 1) were reviewed retrospectively for patient demo-
graphics, comorbidities, presenting clinical manifestations,
results of laboratory tests and imaging studies, treatment with
drugs and devices, and occurrence of cardiac death, cardiac
transplantation, and life-threatening ventricular arrhythmias
through the end of April 2015. Identiﬁcation and conﬁrmation
of arrhythmias were based on retrospective analyses of ICD
reports, 12-lead electrocardiograms, 24- to 48-hour Holter
recordings, and attending physicians’ documentation. The
institutional ethics committee at Helsinki University Central
Hospital approved the study protocol. All participants gave
informed consent. Part of the study population (28 of 59
patients) was included in our recent nationwide study of CS1
that included neither detailed analyses of CMRI nor assess-
ment of its predictive value.
CMRI Protocol
Because of the retrospective nature of our study, several
different scanners were used during the 10-year period from
which the CMRI studies were collected and reanalyzed. The
scanners manufactured by Siemens (Siemens Healthcare)
included the 1.5-T Avantoﬁt (45 studies), the 1.5-T Aera (2
studies), the 1.5-T Sonata (2 studies), the 1.5-T Symphony (1
study), and the 3-T Verio (8 studies). One study was done
using the 1.5-T General Electric SignaHDxt scanner (GE
Healthcare). A 32-channel receiver cardiac coil was used in
all CMRI examinations. Breath-hold cine studies were
performed using retrospectively electrocardiographically
gated segmented true fast imaging with balanced steady-
state free precession. To assess LV and RV volumes and
ejection fraction (EF), cine imaging was done both in vertical
and horizontal long-axis planes and a stack of short-axis
planes covering both ventricles. The typical cine imaging
parameters were repetition time/echo time 3.0/1.6 ms, ﬂip
angle 52°, 2569256 matrix, and 2409340 ﬁeld of view.
Slice thickness was 6 mm, and the interslice gap was 20%.
The temporal resolution was 42 to 49 ms. The typical
imaging parameters of T2-weighted fat saturation images
were repetition time/echo time 1503/45 ms, ﬂip angle 57°,
2569256 matrix, and 2409240 ﬁeld of view. Ten minutes
after intravenous injection of a contrast agent (0.15 mmol/
kg gadoterate meglumine [Dotarem; Guerbet]), LGE images
were acquired in the same views as the cine images using
an inversion-recovery spoiled gradient echo sequence. The
imaging parameters were repetition time/echo time 2.58/
2.3 ms, ﬂip angle 50°, 2569256 matrix, and 2409340 ﬁeld
of view. Slice thickness was 8 mm, and the interslice gap
was 0%. Inversion time was optimized for each measurement
to null the signal intensity of normal myocardium (240–
360 ms).
Figure 1. Diagram depicting the selection of CS patients for
CMRI analyses from the 119 CS patients seen from February
2004 through July 2014. CAD indicates coronary artery disease;
CMRI, cardiac magnetic resonance imaging; CS, cardiac sarcoido-
sis; LGE, late gadolinium enhancement.
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Analyses of CMRI Studies
All CMRI studies were analyzed on a separate workstation
using a dedicated software package (QMass MR 7.60.30.0;
Medis). Studies with insufﬁcient quality for either volumetric
measurements (4 studies) or LGE extent analysis (9 studies)
were excluded (Figure 1). Comprehensive LGE analysis was
prevented by the failure of LV short axis slices to span the
ventricle entirely from base to apex in 7 studies and by poor
image quality in 2 studies. LV and RV volumes and LV mass
were derived by manually drawing LV endo- and epicardial
contours and RV endocardial contours on all short-axis slices
from base to apex at end-diastole and end-systole. Papillary
muscles and endocardial trabeculations were regarded as part
of the ventricular cavity. LV wall thickness was derived
automatically by the software from the end-diastolic contours
and recorded according to the American Heart Association
17-segment model. The presence of marked basal septal
thinning suggestive of scarring, deﬁned as wall thickness
<4 mm in American Heart Association segments 2 and 3, was
separately noted.
In LGE images, the presence or absence of LGE was
initially assessed visually. Epicardial and endocardial end-
diastolic LV contours were traced, as in the cine images.
Regions of interest representing (1) healthy myocardium free
of LGE and (2) myocardium with intense LGE were drawn on a
slice optimally distinguishing healthy from diseased heart
muscle. The extent of LGE as a percentage of LV mass was
calculated automatically by the software. The full width at half
maximum method17 was used for deﬁning the threshold for
LGE: Tissue with a signal intensity >50% of the maximum
signal of the enhanced myocardium was quantiﬁed as scar
tissue. In T2-weighted images, regions of interest were drawn
on remote skeletal muscle and on the LV segments in which
myocardial edema was suspected. Edema was deﬁned as
myocardial signal intensity >1.9-fold the intensity in the
skeletal muscle and classiﬁed as present or absent. All
images were analyzed by a CMRI-trained physician. To assess
repeatability of the LGE data, 10 randomly selected studies
were later reanalyzed blindly by the same physician and by an
independent expert. The repeatability coefﬁcients for the
extent of LGE, determined by the Bland-Altman method,18
were 6.1% and 11.9% for intra- and interobserver
measurements, respectively.
Statistical Analysis
Baseline characteristics are presented as meanSD or as
median (minimum–maximum) for continuous variables and as
frequencies for categorical data. The Pearson r was calculated
when testing for linear correlation between 2 continuous
variables, and the Student t test was used to compare
continuous variables between 2 groups. The end point event
in outcome analyses was a composite of cardiac death,
cardiac transplantation, and life-threatening arrhythmia,
whichever came ﬁrst. Life-threatening arrhythmia was deﬁned
as ventricular ﬁbrillation (VF) or ventricular tachycardia (VT)
requiring external synchronized cardioversion or deﬁbrillation
or ICD therapy (shock or antitachycardia pacing). In survival
analyses, follow-up times were calculated from the date of the
CMRI study. Survival curves were plotted by the Kaplan–Meier
method, and the log-rank test was used to test group
differences in survival. Cox proportional hazards modeling
was used to calculate univariate and multivariate hazard ratios
and the associated 95% CIs and P values. The validity of the
proportional hazards assumption was tested by plotting
Schoenfeld (partial) residuals against ranked survival time.
The assumption was considered valid if no statistically
signiﬁcant time-dependent correlation was observed. P values
<0.05 were considered statistically signiﬁcant in all analyses,
which were performed using SPSS version 21 software for
Macintosh (IBM Corp).
Results
Characteristics of the Study Population
The study population comprised 38 women and 21 men, with
a mean age of 4610 years. In 31 patients (53%), the
diagnosis of CS was conﬁrmed by myocardial biopsy, whereas
27 patients (45%) were diagnosed based on sarcoidosis
histology in mediastinal lymph nodes (n=18), skin (n=4), liver
(n=3), cervical lymph nodes (n=1), or central nervous system
(n=1) combined with cardiac imaging indicative of myocardial
involvement. In addition, 1 patient was diagnosed at autopsy.
Table 1 summarizes the key characteristics of the study
population at the time of CS presentation. As Tables S1
through S3 show, there were no statistically signiﬁcant
differences in any covariate comparisons between included
and excluded patients. This suggests that the baseline
characteristics of our CS patients were representative of the
total CS population seen at our institution during the period
covered by our work. In addition to CS, 13 patients had
history of hypertension and 6 had diabetes, but none had
signiﬁcant renal dysfunction or chronic lung disease aside
from pulmonary sarcoidosis. A total of 15 patients had
extracardiac sarcoidosis involving lungs (n=10), liver (n=3),
skin (n=2), central nervous system (n=1), and bone marrow
(n=1). The remaining 44 patients (75%) had isolated CS.
Signiﬁcant coronary artery disease was excluded by invasive
coronary angiography (n=26), coronary computed tomography
angiography (n=3), treadmill exercise stress test (n=7), and
myocardial perfusion imaging (n=1) or by clinical judgment
alone based on the absence of risk factors, symptoms, and
signs of ischemic heart disease (n=22).
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All 58 patients diagnosed during life prior to transplanta-
tion were administered prednisone as disease-modifying
immunosuppressive therapy. In addition, 31 patients received
azathioprine, 9 received mycophenolate mofetil, 2 received
methotrexate, 2 received inﬂiximab, and 1 patient was given
cyclosporine. ICD was implanted in 35 patients (59%), of
whom 20 received the device for primary prevention and 15
patients received the device after a life-threatening ventricular
arrhythmia. In addition, 13 patients (22%) received a perma-
nent pacemaker. Of the 48 intracardiac devices, 43 were
implanted after CMRI, with a median time interval of
0.5 month (range 0–72 months). Two ICDs and 3 pacemak-
ers were implanted 2 to 22 months prior to CMRI (median
interval 3 months). b-Adrenergic blockers, angiotensin-con-
verting enzyme inhibitors, and amiodarone were given to 58,
40, and 12 patients, respectively. One patient underwent
catheter ablation for frequent VT episodes.
Findings at CMRI
Table 2 summarizes the results of CMRI. Myocardial LGE was
found in all except 2 of the 50 analyzable studies (prevalence
96%), with a median extent of 17% of the LV mass. Myocardial
edema and scar-like interventricular septal thinning (<4 mm)
were less common observations (prevalence 38% and 11%,
respectively). Examples of myocardial LGE and septal thinning
Table 1. Selected Characteristics of the 59 Patients With
Cardiac Sarcoidosis at Presentation
Characteristics Results
Main presenting clinical manifestation
Atrioventricular conduction block 25 (42)
Ventricular tachycardia or fibrillation 18 (31)
Heart failure 13 (22)
Other 3 (5)
New York Heart Association functional class
1 27 (46)
2 25 (42)
3–4 7 (11)
LVEF at echocardiograpy, % 4813
NT-proBNP, pg/mL* 450 (56–6428)
Abnormal cardiac 18F-FDG PET† 28/31 (90)
The data are number (%) of patients, meanSD or median (minimum–maximum). 18F-
FDG PET indicates 18F-ﬂuorodeoxyglucose positron emission tomography; LVEF, left
ventricular ejection fraction; NT-proBNP indicates N-terminal brain natriuretic
propeptide.
*Measurements were made using a commercial assay (Elecsys 2010 or Modular e170;
Roche Diagnostics GmbH) and were available for 56 patients.
†Abnormally increased focal myocardial ﬂuorodeoxyglucose uptake with or without a
perfusion defect (the study was done in 31 of 59 patients).
Table 2. Results of Cardiac Magnetic Resonance Imaging in
the Study Population*
Myocardial LGE present 48/50 (96)
The extent of myocardial LGE, % 17 (2–52)
Myocardial edema present 15/40 (38)
Basal interventricular septal thickness <4 mm 6/55 (11)
Left ventricular ejection fraction, % 4313
Right ventricular ejection fraction, % 5013
Left ventricular end-diastolic volume, mL 20168
Right ventricular end-diastolic volume, mL 16148
Left ventricular mass, g 10933
The data are given as number of patients (%) or meanSD or median (minimum–
maximum). LGE indicates late gadolinium enhancement.
*LGE analyses, myocardial edema analysis, and volumetric measurements were possible
in 50, 40, and 55 patients, respectively, of the 59 patients studied.
A
B
Figure 2. Examples of basal short-axis cardiac
magnetic resonance imaging showing pathological
thinning of the basal septum (A, asterisk) and late
gadolinium enhancement in the interventricular
septum and in the lateral left ventricular wall (B,
white asterisks).
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are shown in Figure 2. LVEF was impaired (<50%) in 36 of 55
patients (65%) and correlated inversely with both plasma N-
terminal brain natriuretic propeptide on admission (r=0.48;
P<0.01) and the extent of LGE (r=0.44; P<0.01). An
impaired RVEF (<50%) was observed in 26 patients (47%).
There was no difference between the means of RVEF in
patients with and without pulmonary sarcoidosis (P=0.958).
Cardiac Events and Predictors of Event-Free
Survival
The total follow-up time from CMRI to the end of the study
varied from 1 to 132 months (median 26 months). Altogether
23 of 59 patients experienced an event contributing to the
composite end point analysis after a median of 15 months of
follow-up (range 1–130 months). The events comprised 3
cardiac deaths (all sudden cardiac arrests), 1 transplantation
due to terminal heart failure, and 19 life-threatening arrhyth-
mias including 5 aborted deaths due to VF and 14 VTs
prompting ICD therapy (n=8) or needing external synchro-
nized shock or deﬁbrillation (n=6). After the end point VT, 1
additional patient died suddenly, 1 underwent transplantation,
and 3 suffered an aborted sudden death owing to VF. Table 3
shows the results of Cox regression analyses on the CMRI
variables as predictors of event-free survival. The univariate
predictors were RVEF, the extent of LGE, and the presence of
scar-like basal interventricular septal thinning (Figure 3) with
no violation of the proportional hazards assumption. In
multivariate analysis involving these 3 measurements, the
extent of LGE by tertiles appeared as an independent
prognostic factor (Table 3). The positive and negative predic-
tive values for an end point event were 50% and 81%,
respectively, for LGE extent >13% (second and third tertiles)
and 75% and 76%, respectively, for LGE extent >22% (third
tertile).
In addition to their relation to the CMRI measurements, the
end point events were associated, without violation of the
proportional hazards assumption, with VT/VF as the present-
ing manifestation of CS (hazard ratio 7.72, 95% CI 3.23–
18.45, P<0.001) and with elevated plasma N-terminal brain
natriuretic propeptide at presentation (hazard ratio 1.07 per
+200 pg/mL difference, 95% CI 1.01–1.10, P=0.016) but not
with either age or sex or New York Heart Association
functional class. A multivariate Cox regression assessing the
predictive value of myocardial LGE extent, plasma N-terminal
brain natriuretic propeptide, and presentation with VT/VF was
done in the 48 patients with complete data available. The
results, given in Table 4, show that each variable was an
independent predictor of event-free survival. Analyzed sepa-
rately in the 41 patients without VT/VF at presentation, LGE
predicted end point events with an hazard ratio of 4.35 (95%
CI 1.33–14.22) per tertile of LGE extent (P=0.015). A
combination of presentation with VT/VF or LGE extent
>22% of LV mass had positive and negative predictive values
for end point events of 74% and 92%, respectively.
Discussion
Our observations show that a comprehensive analysis of
contrast-enhanced CMRI can provide a variety of clues to help
clinicians evaluate the risk of life-threatening cardiac events in
CS. Although extent of myocardial LGE, RVEF, and thickness
of the basal interventricular septum were all predictive of
event-free survival, extent of LGE was the predictor conveying
Table 3. Results of Cox Regression Analyses Involving the Different Cardiac Magnetic Resonance Imaging Measurements as
Predictors of Event-Free Survival in Cardiac Sarcoidosis
Univariate Analysis
HR (95% CI) P Value
Multivariate Analysis*
HR (95% CI) P Value
LVEF, per 5% 0.90 (0.77–1.06) 0.202
LVEDV, per 10 mL 1.01 (0.96–1.06) 0.743
RVEF, per 5% 0.81 (0.69–0.93) 0.004 0.99 (0.96–1.01) 0.277
RVEDV, per 10 mL 1.08 (1.00–1.17) 0.063
LV mass, g 1.05 (0.94–1.17) 0.417
LGE extent
Per 1% 1.05 (1.02–1.09) 0.003
Per tertiles 3.06 (1.56–6.04) 0.001 2.22 (1.07–4.59) 0.032
Myocardial edema present 1.55 (0.53–4.50) 0.425
Thinning of basal septum 3.64 (1.31–10.12) 0.013 1.98 (0.65–6.03) 0.229
HR, hazard ratio; LGE, late gadolinium enhancement; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; RVEDV, right ventricular end-
diastolic volume; RVEF, right ventricular ejection fraction.
*The multivariate model included RVEF, thinning of basal septum, and tertiles of extent of LGE.
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most of the prognostic information from CMRI. Importantly,
extent of LGE retained its prognostic value even after
adjustment for the effects of clinical and laboratory predictors
of outcome.
Life-Threatening Cardiac Events and Survival With
CS
In our recent 25-year nationwide study of CS, the 10-year
cardiac survival estimate was 93%, and the estimate of
transplant-free cardiac survival was 91% in patients diagnosed
clinically and given contemporary treatment with drugs and
devices.1 Although these estimates are better than the earlier
ﬁgures, even for 5-year survival (40–75%),19–21 CS remains a
potentially fatal disease. With current heart failure therapy,
including use of mechanical support devices and heart
transplantation, the overwhelming majority of deaths from
CS are caused by sudden cardiac arrests. In our nationwide
study, 11 of 110 patients underwent heart transplantation
and only 1 patient died of terminal heart failure, whereas 21
patients had either a sudden (n=10) or an aborted sudden
(n=11) arrhythmic death.1 Although an acute complete heart
block may sometimes initiate the cascade of fatal events,
spontaneous ventricular tachyarrhythmias and VF ultimately
arrest the heart in CS. Prevention and management of VT and
VF take priority in today’s clinical care and research of CS,3
especially because rapid progress in the treatment of the
underlying myocardial inﬂammation is unlikely in the near
future. It is worth noting that 22 of 23 end point events
analyzed in this study were attributable to fatal or life-
threatening arrhythmias; heart failure was not an event unless
it was severe enough to lead to transplantation.
CMRI as a Prognostic Study for CS
Two earlier works provided valuable information on the
predictive value of CMRI in CS.11,12 Both were retrospective in
design and relied on the criteria of the Japanese Ministry of
Health and Welfare for diagnosis of CS.22,23 Crawford et al11
studied 51 patients with normal or mildly reduced LVEF
(>35%) and showed that life-threatening arrhythmias during
follow-up (VT/VF, 13 events) were associated with myocardial
LGE, particularly when this was multifocal or involved the right
ventricle. Ise et al12 followed 43 CS patients for a composite
end point of cardiac death, life-threatening ventricular
arrhythmias (VT/VF), and hospitalization for heart failure. Of
the 23 events observed, 16 were related to heart failure (5
deaths and 11 hospitalizations), and 7 were due to ventricular
Figure 3. Kaplan–Meier curves for cardiac survival
free of transplantation and life-threatening arrhyth-
mias by tertiles of LGE extent (A), by absence () or
presence (+) of septal thinning (B), and by RVEF (C).
LGE indicates late gadolinium enhancement; RVEF,
right ventricular ejection fraction.
Table 4. HRs From Multivariate Cox Regression Analysis
Involving Extent of LGE in Cardiac Magnetic Resonance
Imaging, Presentation With VT/VF, and Plasma NT-proBNP on
Admission as Predictors of Event-Free Survival in 48 Patients
With Cardiac Sarcoidosis
Predictors HR (95% CI) P Value
LGE extent, per tertiles 2.27 (1.08–4.77) 0.031
VT/VF as the main presenting clinical
manifestation
9.63 (3.01–30.81) <0.001
NT-proBNP, per +200 pg/mL difference 1.09 (1.02–1.16) 0.008
HR, hazard ratio; LGE, late gadolinium enhancement; NT-proBNP, N-terminal brain
natriuretic propeptide; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
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arrhythmias (1 death and 6 VT/VF). No cardiac transplanta-
tions were reported despite the frequency of severe heart
failure. The extent of myocardial LGE was superior to all other
CMRI variables (including LVEF) in predicting event-free
survival and retained its signiﬁcance even after adjustment
for the prognostic effects of New York Heart Association
functional class and plasma brain natriuretic peptide. Our
ﬁndings support these 2 data sets but also add to the
knowledge by identifying impaired RVEF and basal septal
thinning as CMRI variables portending poorer outcome. The
predictive value of RV function had also been suggested in an
earlier study by Schuller et al24 revealing that RV dysfunction,
shown by echo, nuclear imaging, or MRI, predicted life-
threatening arrhythmias in CS patients with an ICD. In
addition, the data of Crawford et al11 and Blankstein et al25
suggest that life-threatening arrhythmic events in CS may be
related to inﬂammatory involvement of the RV wall. Unfortu-
nately, we could not distinguish whether RV dysfunction in our
patients resulted mainly from direct RV involvement or from
LV disease-related pulmonary hypertension.
Scar-like thinning of the basal interventricular septum at
echocardiography has long been known as a typical but
nonspeciﬁc diagnostic sign of CS.26 In a very recent
retrospective analysis of echocardiographic studies in 74
patients with CS, Nagano et al27 showed that basal septal
thickness <4 mm (or ≤60% of middle septal thickness)
predicted future symptomatic arrhythmias and admissions
for heart failure. Our work showed that a comparable
degree of septal thinning by CMRI also predicted serious
events, mainly fatal and life-threatening ventricular arrhyth-
mias, even if not incrementally to the prognostic value of
myocardial LGE extent. The low prevalence (11%) of septal
thinning, as deﬁned in this study (<4 mm), limits its value
as an outcome predictor. As shown in Figure 3B, the great
majority of end point events were seen in patients without
septal thinning.
Could Myocardial LGE Help Select Patients for
ICD Implantation in CS?
According to the expert consensus statement of the Heart
Rhythm Society,3 ICD implantation “is recommended” (class 1
indication) in CS for patients with spontaneous sustained
ventricular arrhythmias or LVEF <35%. Furthermore, ICD “can
be useful” (class 2a indication) for patients with (1) an
indication for permanent pacemaker, (2) unexplained syncope
or near syncope felt to be arrhythmic in origin, or (3) inducible
sustained VT or relevant VF. Finally, ICD “may be considered”
(class 2b indication) in patients with LVEF between 36% and
49% and/or RVEF <40%. The last recommendation was based
mainly on 3 cohorts of CS patients with an ICD showing that
ICD therapies were common, even in patients with mildly
reduced LVEF.2,24,28 The value of myocardial LGE as an
indication for an ICD in patients with normal LVEF was
considered but dismissed by the experts.3 We think that the
late observations on the predictive value of myocardial LGE,
summarized in Table 5, call for a reevaluation of the
recommendation at this point. Importantly, LGE predicted
cardiac events despite normal or mildly reduced LV func-
tion,11 and in the study by Ise et al12 and in our study, it even
outperformed LVEF, the key prognostic factor in CS reported
previously.1,2,8,24,29 It is worth discussing whether some
deﬁnition of myocardial LGE, for example, extent ≥22% of LV
mass or involvement of the RV wall or involvement of ≥9 of 29
combined LV and RV segments (Table 5), should be added as
a new or strengthening indication for an ICD in patients with
CS and normal or mildly reduced LV function. In our study,
extent of LGE had prognostic value over and above the
Table 5. Summary of Reports Describing the Value of LGE at CMRI as a Predictor of Serious Cardiac Events in CS
Study
Number of
Patients
Follow-up,
Months Composite End Point Events
Number of
Events CMRI Finding
Predictive Value for End
Point Events
Positive, % Negative, %
Crawford et al11 51 48 (mean) Death or VT/VF 15 LGE ≥6% of LV mass 58 91
LGE in ≥9 of 29 segments* 72 97
RV LGE present 100 95
Ise et al12 43 39 (mean) Cardiac death, VT/VF or
hospitalization for heart failure
23 LGE ≥21.9% of LV mass 62 86
Present work 59 26 (median) Cardiac death, VT/VF or
transplantation
23 LGE >22% of LV mass 75 76
LGE >22% of LV mass or
VT/VF at CS presentation
74 92
CMRI indicates cardiac magnetic resonance imaging; CS, cardiac sarcoidosis; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular; VF, ventricular ﬁbrillation; VT,
ventricular tachycardia.
*Seventeen LV and 12 RV segments.
DOI: 10.1161/JAHA.115.003040 Journal of the American Heart Association 7
Magnetic Resonance Imaging in Cardiac Sarcoidosis Ekstr€om et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
signiﬁcance of presenting life-threatening arrhythmias, sug-
gesting it could genuinely help clinicians decide which
patients need an ICD for primary prevention.
Strengths and Limitations
A major strength of our work was that the diagnosis of CS
was based on myocardial histology in the majority of
patients and conformed to the latest diagnostic criteria3 in
the remainder. Most of the comparable previous
work11,12,19,24,25,27 relied mainly on the Japanese diagnostic
criteria,22,23 which suffer from problems with sensitivity and
speciﬁcity3,4,8,10,29 and are no longer endorsed by experts
in the ﬁeld.3 The generic limitations of retrospective studies
apply to our work, as they do to all other outcome data in
CS because of the lack of prospective research. It is also
worth recognizing that our study population may have been
skewed toward the severe end of the CS spectrum because
ours is the only transplant center in Finland. Our study was
relatively small in size, and we had to reject a modest part
(15%) of the LGE studies from analyses because of quality
problems. Still, we believe the number of end point events
in LGE analyses (20 events in 50 patients) was sufﬁcient
for meaningful survival analyses.30 Our composite end point
event of life-threatening arrhythmias consisted of VF (fatal if
not treated) and sustained VT requiring ICD therapy or
external cardioversion or deﬁbrillation. It is quite likely that
not all of the VTs prompting appropriate ICD therapy would
have resulted in cardiac arrest at the time of the event.
Finally, it is also a limitation that LGE of the RV free wall
was not studied.
Conclusions
Our study suggests that carefully analyzed CMRI helps predict
serious cardiac events in patients with CS. The extent of
myocardial LGE in particular appears to contain useful
prognostic information. We recommend its routine measure-
ment and inclusion in the assessment of the risk of life-
threatening cardiac events in CS.
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SUPPLEMENTAL MATERIAL 
 
 
Table S1. Comparison of CS patients with and without CMRI data 
 
Present study (n=59) 
No CMRI done 
(n=59) 
p 
Main presenting clinical manifestation, n 
   
              Atrioventricular conduction block 25 33 0.141 
              Ventricular tachycardia or fibrillation 18 11 0.134 
              Heart failure 13 11 0.647 
              Other 3 4 0.697 
New York Heart Association functional class 
   
             I  27 21 0.261 
             II 25 27 0.711 
 III – IV 7 10 0.432 
Left ventricular ejection fraction at 
echocardiograpy, % 
48 ±13  45 ±16  0.297 
NT-proBNP, pg/mL     450 (56 - 6428) 363 (85 - 23022) 0.102 
Abnormal cardiac 
18
F-FDG PET  28/31 28/35 0.243 
Data are number of patients, mean±standard deviation or median and range in parentheses 
NT-proBNP indicates N-terminal brain natriuretic propeptide; 
18
F-FDG PET, 
18
F-
fluorodeoxyglucose positron emission tomography. 
 
 
 
 
 
 
 
 
 
 
Table S2. Comparison of patients with and without quality cine CMRI images   
  
 
Good quality cine 
(n=55) 
Excluded due to  
cine quality (n=4) 
p 
Main presenting clinical manifestation, n 
  
               Atrioventricular conduction block 23 2 0.749 
              Ventricular tachycardia or fibrillation 18 0 0.170 
              Heart failure 11 2 0.162 
              Other 3 0 0.632 
New York Heart Association functional class 
  
              I  26 1 0.388 
             II 23 2 0.749 
 III – IV 6 1 0.400 
Left ventricular ejection fraction at 
echocardiograpy, % 
47 ±13  55 ±11  0.263 
NT-proBNP, pg/mL     476 (56 - 6428) 324 (67 - 1460) 0.574 
Abnormal cardiac 
18
F-FDG PET  25/28  3/3 0.551 
Data are number of patients, mean±standard deviation or median and range in parentheses 
NT-proBNP indicates N-terminal brain natriuretic propeptide; 
18
F-FDG PET, 
18
F-
fluorodeoxyglucose positron emission tomography. 
 
 
 
 
 
 
 
 
 
 
 
Table S3.  Comparison of patients with and without quality LGE CMRI images   
 
Good quality 
LGE (n=50) 
Excluded due to 
LGE quality (n=9) 
p 
Main presenting clinical manifestation, n 
 
                Atrioventricular conduction block 20 5 0.385 
              Ventricular tachycardia or fibrillation 16 2 0.558 
              Heart failure 11 2 0.988 
              Other 3 0 0.451 
New York Heart Association functional class 
 
               I  21 6 0.277 
             II 23 2 0.278 
 III – IV 6 1 0.939 
Left ventricular ejection fraction at 
echocardiograpy, % 
47 ±13  50 ±12  
0.651 
NT-proBNP, pg/mL * 439 (56 - 6428) 580 (85-1291) 0.315 
Abnormal cardiac 
18
F-FDG PET † 22/23 6/8 0.156 
Data are number of patients, mean±standard deviation or median and range in parentheses 
NT-proBNP indicates N-terminal brain natriuretic propeptide; 
18
F-FDG PET, 
18
F-
fluorodeoxyglucose positron emission tomography. 
 
 
